The Insurer's Moat: How One Policy Cements a Med-Tech Leader's Reign

WESTBOROUGH, Mass. – July 15, 2026 – A seemingly routine medical policy revision from BlueCross BlueShield of Tennessee (BCBSTN) has sent a powerful signal across the medical technology landscape. Effective July 31, the insurer has reaffirmed its coverage for Echosens' FibroScan®, a non-invasive liver diagnostic tool, while classifying emerging competitor technologies as “investigational.” This decision is far more than a clinical footnote; it is a textbook example of how payers act as the ultimate gatekeepers of innovation, building formidable commercial moats around established market leaders.

For Echosens, the announcement is a resounding strategic victory. By securing its status as “medically necessary,” the company not only protects a vital revenue stream in a key market but also gains a powerful endorsement it can leverage with other insurers nationwide. For challengers like Mindray and Eieling, however, the policy is a significant barrier, effectively freezing their market penetration in Tennessee and underscoring the immense challenge of unseating an incumbent armed with a deep well of clinical evidence.

The Power of the Payer

In the high-stakes world of medical devices, FDA clearance is merely the ticket to the game; insurance coverage is how you win. The updated BCBSTN policy on noninvasive liver imaging makes this distinction crystal clear. While continuing to cover FibroScan® for evaluating and monitoring chronic liver disease, the policy explicitly deems alternative transient elastography techniques—including ViTE from Mindray and MAP from Eieling—as investigational, citing “insufficient evidence.”

This single word, “investigational,” is a commercial death knell for routine clinical use. It means providers who use these alternative devices will not be reimbursed, creating a powerful disincentive to purchase or operate the equipment. The decision effectively solidifies a de facto monopoly for Echosens within the vast BCBSTN network.

In the official press release, Amy Conner, MPH, Director of Market Access and Pharma at Echosens, framed the move as a benefit for clinicians. “The updated policy provides additional clarity for providers by distinguishing between noninvasive technologies that may appear similar but have different evidence bases and coverage determinations,” she stated. While true, this corporate-speak elegantly papers over a brutal competitive reality: Echosens didn't just win a debate over clinical evidence; it reinforced its fortress walls. The policy provides clarity, but that clarity directs all traffic down a single, Echosens-paved road.

Evidence as a Competitive Weapon

The rationale behind BCBSTN’s decision lies in the deep chasm of clinical validation separating FibroScan® from its rivals. Echosens, a pioneer in the field, has spent years and untold capital building an unparalleled library of proof. The company boasts of its technology's validation in over 5,600 peer-reviewed publications and its inclusion in nearly 220 international guidelines. This is not just scientific rigor; it is a strategic asset, a barrier to entry so high that few can surmount it.

In contrast, competing technologies are still in the early stages of this marathon. Mindray’s ViTE and Eieling’s Liverscan C have both secured FDA clearance and can point to promising studies demonstrating high correlation with FibroScan®'s results. Some studies even suggest potential advantages, such as the real-time B-mode ultrasound guidance integrated into their systems. However, a handful of positive studies pales in comparison to the mountain of longitudinal data and global guideline acceptance that FibroScan® enjoys. Payers like BCBSTN are inherently conservative; they bet on established track records, not on promising potential. For them, the thousands of publications supporting FibroScan® represent a low-risk, evidence-backed decision that is easy to defend.

This dynamic reveals a critical lesson for the med-tech industry: the race is not just to innovate, but to validate. The long, arduous, and expensive process of generating overwhelming clinical evidence is the true cost of market leadership. Without it, even a superior technology can be relegated to “investigational” purgatory.

On the Ground: The Clinical and Financial Realities

For healthcare providers in Tennessee, the policy update is a double-edged sword. On one hand, it offers unambiguous guidance on billing. The policy’s reference to specific CPT codes—76981 for elastography with image guidance and 91200 for procedures without—removes administrative guesswork. Providers know that using FibroScan® will lead to predictable reimbursement, a crucial factor for the financial health of any practice. With Medicare reimbursement rates hovering around $122 for the imaging-guided procedure (76981) versus just $34 for the non-imaging code (91200), the incentive to use a compliant, covered technology is immense.

On the other hand, the policy curtails clinical autonomy. A physician who believes a competing device offers a better assessment for a specific patient, perhaps due to obesity or other complicating factors, is now faced with a difficult choice: use the covered but potentially less-preferred option, or ask the patient to pay out-of-pocket for an “investigational” procedure. This dynamic limits patient access to newer technologies and can stifle the adoption of innovation at the clinical level.

A Competitive Battleground Solidified

The non-invasive liver diagnostics market is a lucrative and growing field, projected to double from $3 billion in 2021 to $6 billion by 2031. It is a prize worth fighting for. But the BCBSTN policy illustrates just how entrenched the leader, Echosens, has become. This is not merely a win in Tennessee; it is a case study that Echosens’ market access team will undoubtedly carry into negotiations with every other major insurer in the country.

For challengers like Mindray and Eieling, the path forward has become steeper. Their strategy must now be twofold: continue to innovate on the technology front while simultaneously launching the large-scale, multi-center, long-term clinical trials needed to build an evidence portfolio that can rival the incumbent's. It is a costly and time-consuming endeavor with no guarantee of success. They are not just competing on features and price; they are competing against a two-decade head start in the grueling race for clinical validation. This policy decision serves as a stark reminder that in the business of healthcare, the most powerful story is the one told by the data.